Skip to main content
LEGN
NASDAQ Life Sciences

Legend Biotech's LB2501 Achieves 100% ORR, 83% CR in Phase 1 Lymphoma Study, Establishing Clinical Proof-of-Concept

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$35.87
Mkt Cap
$6.662B
52W Low
$16.24
52W High
$45.297
52W Position info
121% above low
Off High info
21% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

LEGN has more than doubled off its 52-week low of $16.24.

Summary

Legend Biotech announced compelling clinical proof-of-concept data for its investigational LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma. At the higher dose level, LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response (CR) in six patients. This follows earlier reports of strong preliminary Phase 1 data for LB2501 on June 2nd, now providing specific, highly positive efficacy numbers and a formal proof-of-concept. The therapy also demonstrated a favorable safety profile with no lymphodepletion required, a significant advantage for in vivo CAR-T. These results are exceptionally strong for an early-stage study in a difficult-to-treat patient population, significantly de-risking the program and highlighting LB2501's potential as a first-in-class therapy. The ability to generate CAR-T cells in vivo without lymphodepletion could simplify treatment and expand patient access.

At the time of this announcement, LEGN was trading at $35.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $16.24 to $45.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LEGN - Latest Insights

LEGN
Nov 10, 2026, 7:11 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $24.43
Real-time Price: $16.15 info
Change: -$8.29 (-34%) info
Market Cap: $3.125B info
LEGN
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $23.76
Real-time Price: $16.15 info
Change: -$7.62 (-32%) info
Market Cap: $3.125B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $19.11
Real-time Price: $16.15 info
Change: -$2.97 (-16%) info
Market Cap: $3.125B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.10
Real-time Price: $16.15 info
Change: -$2.96 (-15%) info
Market Cap: $3.125B info
LEGN
Oct 13, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.10
Real-time Price: $16.15 info
Change: -$1.96 (-11%) info
Market Cap: $3.125B info